BiotechTube

branaplam

Phase 1/2Completed
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spinal Muscular Atrophy

Conditions

Spinal Muscular Atrophy

Trial Timeline

Apr 2, 2015 → Dec 29, 2022

NCT ID
NCT02268552

About branaplam

branaplam is a phase 1/2 stage product being developed by Novartis for Spinal Muscular Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT02268552. Target conditions include Spinal Muscular Atrophy.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT02268552Phase 1/2Completed

Competing Products

20 competing products in Spinal Muscular Atrophy

See all competitors
ProductCompanyStageHype Score
SUN13837 injection + PlaceboDaiichi SankyoPhase 2
52
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mgAstellas PharmaPhase 2
52
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 2
52
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 1
33
ElezanumabAbbViePre-clinical
23
Elezanumab + PlaceboAbbViePhase 2
52
Ropivacaine + BupivacaineAstraZenecaPhase 3
77
Onasemnogene Abeparvovec-xioiNovartisPhase 1
33
ZolgensmaNovartisPre-clinical
23
BVS857 + PlaceboNovartisPhase 2
52
AVXS-101NovartisPhase 1
33
Onasemnogene Abeparvovec-xioiNovartisPhase 3
77
Onasemnogene Abeparvovec-brveNovartisApproved
85
Onasemnogene Abeparvovec-xioiNovartisPre-clinical
23
Onasemnogene Abeparvovec-xioiNovartisPhase 3
77
Onasemnogene Abeparvovec-xioiNovartisPhase 3
77
onasemnogene abeparvovecNovartisPhase 3
77
onasemnogene abeparvovec-xioiNovartisPhase 3
77
RisdiplamRochePhase 1
33
ATI355NovartisPhase 1
33

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85